Integris Partners recently advised Chata Biosystems, Inc. in the sale of its Solutions and Instruments Business to Boval Company, LP, a Cleburne, Texas based manufacturer of cell culture and diagnostic biological raw materials. Boval has acquired the Chata Biosystems name as part of the acquisition.

“Integris Partners was able to identify and generate interest from a buyer that would never have crossed our radar in the ordinary course of business, and was able to show how the combination of these two product sets would be able to complement each other and result in significant synergies and growth opportunities. We were previously unaware of Boval, and are confident that the Chata product lines will continue their dynamic grow under the new parent,” said Ted Ziemann, Chata Chairman and CEO.

Cody Yarborough, Boval President, stated, “We are in the middle of building a highly dynamic company with a diversified portfolio of offerings for our customers in the life sciences, biotechnology and biofuels industries. Integris Partners was able to demonstrate to us that the addition of Chata to our existing business would add tremendous value and make us that much more important to our customers.”

The remaining Chata Biosystems, Inc. will change its name to CHD Bioscience, Inc. and focus on continued development of its emerging group of proprietary disinfectants, which provide a highly effective and environmentally safe approach to combatting serious issues of infectious diseases in hospitals, clinics, and other institutions.

Terms of the transaction were not disclosed. For additional information, please contact
Stephen van den Heever.